Brief: Alterity Therapeutics Enrolls First Patient In Italy In Phase 2 Trial In Multiple System Atrophy
08/03/2023 12:38
March 8 (Reuters) - Alterity Therapeutics Ltd ATH.AX :
* ALTERITY THERAPEUTICS ENROLLS FIRST PATIENT IN ITALY IN
ATH434
PHASE 2 CLINICAL TRIAL IN MULTIPLE SYSTEM ATROPHY
Source text for Eikon: ID:nGNXbxfdTn
Further company coverage: ATH.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital